CureVac Cash on Hand 2021-2021 | CVAC
CureVac cash on hand from 2021 to 2021. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
CureVac Annual Cash on Hand
(Millions of US $) |
| 2021 |
$916 |
| 2020 |
$1,514 |
| 2019 |
$ |
CureVac Quarterly Cash on Hand
(Millions of US $) |
| 2021-12-31 |
$916 |
| 2020-12-31 |
$1,514 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$3.505B |
$0.116B |
|
CureVac B.V. is a clinical-stage biopharmaceutical company. It engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102. CureVac B.V. is based in Germany.
|
